Welcome to our dedicated page for Collegium Pharmaceutical news (Ticker: COLL), a resource for investors and traders seeking the latest updates and insights on Collegium Pharmaceutical stock.
News about Collegium Pharmaceutical, Inc. (Nasdaq: COLL) focuses on its activities as a biopharmaceutical company with a portfolio spanning responsible pain management and neuropsychiatry. The company regularly issues press releases on product-related research, financial performance, capital structure, and corporate initiatives, providing investors and healthcare professionals with insight into its operations.
A major theme in Collegium’s news flow is the development and commercialization of JORNAY PM, a central nervous system stimulant indicated for the treatment of ADHD in people 6 years of age and older. The company highlights real-world data on JORNAY PM at scientific meetings such as the American Professional Society of ADHD and Related Disorders (APSARD), the American Academy of Child & Adolescent Psychiatry, and the Neuroscience Education Institute conferences. Releases describe poster presentations on dosing, comparative outcomes versus other ADHD treatments, and changes in functioning and psychiatric symptoms in various patient groups.
Collegium also issues news on its pain portfolio, including BELBUCA and XTAMPZA ER. At events like PAINWeek, the company presents multiple posters that examine treatment characteristics, safety, economic burden, and clinical outcomes for patients with chronic pain. These communications underscore Collegium’s focus on responsible pain management and real-world evidence generation.
Investors following COLL can find regular updates on quarterly financial results, guidance, and non-GAAP metrics such as adjusted EBITDA in the company’s earnings press releases. Additional news covers capital deployment, including share repurchase authorizations and the closing of a syndicated credit facility, as well as participation in healthcare and investor conferences. For those tracking developments in ADHD treatment and opioid-based pain therapies, the Collegium news page offers an organized view of clinical data, commercial progress, and financial disclosures over time.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) has been recognized as one of Boston Business Journal’s 2020 Best Places to Work. CEO Joe Ciaffoni expressed honor at the recognition, attributing it to the commitment of their talented team towards responsible pain management. The rankings are based on employee surveys evaluating work environment, job satisfaction, and more.
This acknowledgment underscores the company's efforts in creating a positive workplace culture, enhancing its reputation within the industry.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) reported significant financial results for Q1 2020. The company achieved GAAP profitability with a net income of $0.5 million, contrasting a net loss of $9.7 million in Q1 2019. Non-GAAP net income reached $31.2 million. Xtampza ER prescriptions surged by 30% year-over-year. The company also closed the acquisition of Nucynta rights, which contributed positively to revenue growth. However, it revised its 2020 financial guidance due to COVID-19 impact, lowering expected revenues for Xtampza ER from $150-$160 million to $130-$140 million.